Gene therapy for advanced Parkinson's disease using brain surgery
Part of Brain & nervous system clinical trials.
This early-stage trial tests a new gene therapy delivered directly into a specific brain region (the subthalamic nucleus) using stereotactic surgery. It's designed for people with advanced Parkinson's disease who no longer respond well to standard medications or have severe side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 40–70 years old
- Advanced Parkinson's disease (Hoehn & Yahr stage 4–5) diagnosed at least 5 years ago
- Currently taking levodopa (a Parkinson's medication) with good response for at least 12 months
- Moderate-to-severe motor symptoms or significant medication side effects despite treatment
- Stable on current medications for at least 4 weeks before enrollment
- Able to commit to 12 months of follow-up visits and no other brain surgery during that time
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy called ZR001 for people with Parkinson's disease. It involves a one-time surgery to inject the therapy into the brain, and researchers want to see if it's safe and can help improve movement symptoms.
This trial tests a gene therapy (AAV2-hAADC) delivered directly into the brain to help people with advanced Parkinson's disease whose medication doesn't work as well as it used to. The goal is to improve the brain's ability to make dopamine and reduce daily 'off' time.
This study tests a new gene therapy called LY-N001, which is injected directly into the brain. It is for people with moderate to advanced Parkinson's disease who have a specific genetic change in the GBA1 gene. The goal is to see if this treatment is safe and can help improve symptoms.
This early-stage trial tests NouvNeu001, a new cell-based treatment injected into the brain for people with moderate-to-advanced Parkinson's disease who have already had deep brain stimulation or brain surgery. The goal is to see if it can reduce Parkinson's symptoms when standard treatments are no longer working well.
This study tests a new cell therapy called bemdaneprocel to see if it can reduce Parkinson's symptoms and “off” time. The treatment involves transplanting special cells into the brain to help replace lost dopamine-producing cells.
This trial tests a gene therapy for people with advanced Parkinson's disease (at least 10 years since diagnosis). It uses a special infusion to deliver treatment directly into the brain. The goal is to see if it can improve motor symptoms.
Hear when a new Parkinson's Disease (PD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.